AI Article Synopsis
- The rise of new types of kidney tumors, especially those defined by specific molecular characteristics, is creating challenges for pathology labs due to their rarity and lack of clear features.
- Diagnosing these tumors requires identifying specific molecular changes, which many labs are not equipped to handle due to limited resources or cost issues.
- Pathologists need to stay informed about the latest developments in renal neoplasms and understand the constraints of their current diagnostic capabilities.
Article Abstract
The recent influx of novel renal neoplasms, particularly molecularly-defined renal carcinomas, has introduced new challenges in the daily practice of most pathology laboratories. These tumors are uncommon, they do not always have well-established morphologic features, and the expression profile of most common biomarkers is not well understood. Moreover, the diagnosis of molecularly-defined renal carcinomas requires the documentation of the disease-defining molecular alteration, with molecular studies or surrogate immunohistochemical markers. Unfortunately, most pathology laboratories lack molecular laboratories, or it is not cost-effective to maintain assays of the specific biomarkers in these unusual tumors. Pathologists should have updated knowledge about the recent changes in renal neoplasms and be aware of these limitations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10668969241231982 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrated RNA sequencing analysis and machine learning identifies a metabolism-related prognostic signature in clear cell renal cell carcinoma.
Sci Rep
January 2025
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
The connection between metabolic reprogramming and tumor progression has been demonstrated in an increasing number of researches. However, further research is required to identify how metabolic reprogramming affects interpatient heterogeneity and prognosis in clear cell renal cell carcinoma (ccRCC). In this work, single-cell RNA sequencing (scRNA-seq) based deconvolution was utilized to create a malignant cell hierarchy with metabolic differences and to investigate the relationship between metabolic biomarkers and prognosis.
View Article and Find Full Text PDFLeveraging explainable AI and large-scale datasets for comprehensive classification of renal histologic types.
Sci Rep
January 2025
Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Korea.
Recently, as the number of cancer patients has increased, much research is being conducted for efficient treatment, including the use of artificial intelligence in genitourinary pathology. Recent research has focused largely on the classification of renal cell carcinoma subtypes. Nonetheless, the broader categorization of renal tissue into non-neoplastic normal tissue, benign tumor and malignant tumor remains understudied.
View Article and Find Full Text PDFBelzutifan for renal cell carcinoma: Balancing regulatory approval with societal and patient impact.
Med
January 2025
Department of Genitourinary Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
LITESPARK-005 evaluated belzutifan against everolimus in advanced renal cell carcinoma (RCC), demonstrating significant progression-free survival improvement but failing to meet the overall survival (OS) co-primary endpoint. Despite FDA approval, the trial highlights key obstacles in drug development in RCC, given the absence of OS improvement, lack of biomarker studies, high financial toxicity, and limited accessibility outside the United States.
View Article and Find Full Text PDFTranscription factor MAZ activates the transcription of hypomethylated TYMP in ccRCC.
Funct Integr Genomics
January 2025
School of Medical Technology, Tianjin Medical University, Tianjin, 300203, China.
Clear cell renal cell carcinoma (ccRCC) is a highly malignant tumor characterized by a significant propensity for recurrence and metastasis. DNA methylation has emerged as a critical epigenetic mechanism with substantial utility in cancer diagnosis. In this study, multi-omics data were utilized to investigate the target genes regulated by the transcription factor MYC-associated zinc finger protein (MAZ) in ccRCC, leading to the identification of thymidine phosphorylase (TYMP) as a gene with notably elevated expression in ccRCC.
View Article and Find Full Text PDFRSK4 promotes the metastasis of clear cell renal cell carcinoma by activating RUNX1-mediated angiogenesis.
Cancer Biol Ther
December 2025
State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital, Air Force Military Medical University, Xi'an, China.
Ribosomal S6 protein kinase 4 (RSK4), a member of the serine‒threonine kinase family, plays a vital role in the Ras‒MAPK pathway. This kinase is responsible for managing several cellular activities, including cell growth, proliferation, survival, and mobility. In this study, we observed higher RSK4 protein expression in clear cell renal cell carcinoma (ccRCC) than in normal kidney tissue, and the overexpression of RSK4 might predict poor outcomes for ccRCC patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!